Skip to Content

Join the 'Proben-C' group to help and get support from people like you.

Proben-C News

Newly-Published Colchicine Safety Data Provide First Evidence-Based Dosing Guidance to Avoid Potentially Serious Interactions With Commonly Prescribed Drugs

Posted 11 Aug 2011 by Drugs.com

- Paper Published in August Issue of Arthritis & Rheumatism Highlights Several Previously Unknown Drug-Drug Interactions - Colchicine Dose Reductions Necessary in Presence of Certain CYP3A4 or P-gp Inhibitors - Studies Supported URL Pharma Clinical Research Program that Led to FDA Approval of Colcrys® PHILADELPHIA, Aug. 11, 2011 /PRNewswire/ – Newly-published results from a series of colchicine safety studies provide physicians with the first evidence-based dosing guidance for colchicine when co-administered with certain commonly prescribed drugs, helping doctors and patients avoid serious and potentially life-threatening drug-drug interactions. The study results, published in a paper titled "Evidence Basis of a Novel Colchicine Dose Reduction Algorithm to Predict and Prevent Colchicine Toxicity in the Presence of P-gp/CYP450 3A4 Inhibitors," appear in the August issue of Arthritis ... Read more

Related support groups: Colchicine, Colcrys, Proben-C, Probenecid and Colchicine, Colchicine/Probenecid

Ask a Question

Further Information

Related Condition Support Groups

Gouty Arthritis

Proben-C Patient Information at Drugs.com